Jennifer Moseley

Jennifer is the Vice President of Clinical Operations and Innovation at Immunovant. She has more than 25 years of drug development experience in the areas of global operations, program management, clinical operations, CRO oversight and management and operational excellence in clinical trial delivery. Prior to joining Immunovant, Ms. Moseley was an Executive Director at Astellas, where she was responsible for the managing program delivery teams, supporting regulatory filings and clinical inspection activities, operational excellence initiatives, and was the Astellas TransCelerate Operational Committee representative for the past 2 years. Prior to Astellas, Ms. Moseley spent 16 years at Abbott/AbbVie where she was responsible for clinical operations in a variety of therapeutic areas across early and late-stage development programs. She contributed to the clinical development, global submissions, and approvals for KaletraTM and Viekira PakTM, two novel antiviral therapeutics that led to new treatment paradigms for AIDs and HCV patients, respectively.

Jennifer holds a B.Sc. in Microbiology from the University of Illinois at Urbana-Champaign.